Overactive bladder/enuresis:

Indications for VESICARE:

Overactive bladder with symptoms of urge urinary incontinence, urgency, and frequency.


Swallow whole with water. Initially 5mg once daily; if well tolerated, may increase to 10mg once daily. Severe renal impairment (CrCl<30mL/min), moderate hepatic impairment (Child-Pugh B), or concomitant potent CYP3A4 inhibitors: max 5mg once daily.


Not established.


Gastric or urinary retention. Uncontrolled narrow-angle glaucoma.


Severe hepatic impairment: not recommended. Bladder outflow obstruction. Decreased GI motility. Controlled narrow-angle glaucoma. History of QT prolongation. Monitor for CNS effects esp. after initiation or dose increases; consider reducing dose or discontinue if occurs. Renal or hepatic impairment. Exposure to high environmental temperature. Labor & delivery. Pregnancy (Cat.C). Nursing mothers: not recommended.

Pharmacologic Class:

Muscarinic antagonist.


Potentiated by potent CYP3A4 inhibitors (eg, ketoconazole); see Adult. May be antagonized by CYP3A4 inducers. Avoid drugs known to prolong the QT interval. Additive anticholinergic effects with other anticholinergics.

Adverse Reactions:

Dry mouth, constipation, UTI, blurred vision; angioedema (discontinue if occurs), CNS effects (eg, headache, confusion, hallucination, somnolence); rare: anaphylactic reactions.


Hepatic (CYP3A4). 98% protein bound.


Renal (major), fecal (minor).

Generic Availability:


How Supplied:

Tabs—30, 90

Pricing for VESICARE

10mg tablet (Qty: 30)
Appx. price $19